QST's Heat-Etched Nanodiamond Quantum Sensors Cut Particle-to-Particle Variation to a Quarter and Raise the Signal 55 Percent: ACS Nanoscience Au, 7 October 2026
Uniform nanodiamond quantum sensors for blood diagnostics
Quentir Medicine Monitor
Evidence-based insights for quantum medicine.
A diagnostic test is only useful when it gives the same answer for the same sample, whichever batch of reagent the laboratory happens to open that morning. Tiny diamond particles that act as quantum sensors have shown remarkable sensitivity in research settings, yet each particle has behaved slightly differently, and that spread has stood between the laboratory result and a test a hospital could rely on.
On 7 October 2026 Japan's National Institutes for Quantum Science and Technology (QST), with Chiba University, Institute of Science Tokyo, Kyoto University and the Chiba start-up Type-I Technologies, reported a new way to make nanodiamond quantum sensors that behave far more alike. According to the QST press release of 7 October 2026, the new process reduces particle-to-particle variation to about a quarter of that of conventional particles and raises the quantum signal by 55 percent. The groups see the work as groundwork for quantum liquid biopsy, the detection of very small amounts of disease-related molecules in blood, and for batch production of uniform sensors rather than hand-picking a few outstanding particles.
The paper, "Spin-Uniform Nanodiamond Quantum Sensors for Reproducible Intracellular Thermometry," by Chihiro Suzuki, Ryuji Igarashi and nine co-authors, appeared online in ACS Nanoscience Au (DOI 10.1021/acsnanoscienceau.6c00068) on the same day. For a laboratory director, a diagnostics buyer or a clinician following early cancer detection, it addresses the question that comes before any claim of sensitivity: whether two sensors given the same sample report the same value.
A nanodiamond sensor depends on a defect called the nitrogen-vacancy center, a spot in the diamond lattice where a nitrogen atom sits next to a missing carbon atom. When green laser light falls on the particle, the defect glows red, and microwave measurements of that glow, a method called optically detected magnetic resonance (ODMR), reveal small changes in temperature and in the chemical surroundings. Particles a few tens to a few hundred nanometers across can enter living cells.
The conventional route crushes larger diamond into nanoparticles first and creates the sensing defects afterward. QST explains that mechanical crushing leaves scratches and strain that differ from particle to particle, so every particle carries its own quirks into the measurement. The new process reverses the order. The team first builds nitrogen-vacancy centers into relatively large diamond particles of good crystal quality, then heats them gently in air so that the surface oxidizes away a little at a time. Diamond faces oxidize at different rates, and the researchers tuned the conditions so that disordered outer material goes first. What remains is the most orderly central tenth of the original particle, still small enough for work inside cells.
Which Blood Signal Rewards a Quantum Kernel
A screening gap a blood draw might close
Annual low-dose CT screening lowers lung cancer mortality, and most of the people who qualify for it are not up to date with it. The American Cancer Society reported in June 2024 that 18.1 percent of screening-eligible US adults were up to date in 2022 survey data, which leaves the larger share of a proven survival benefit unclaimed. Blood-based tests are attractive because collection is easier to distribute and to repeat than a CT appointment. The study compares two molecular readouts, drawn from a wider field that also includes mutation panels, circulating proteins and cell-free RNA: cell-free DNA fragmentomics, which reads the length and position of circulating fragments, and methylation, which reads chemical marks at defined genomic targets. Both produce high-dimensional, nonlinear data, and both are degraded by the heterogeneity of lung cancer.
What the Cleveland Clinic and IBM Quantum preprint reports
A team from Cleveland Clinic Research and IBM Quantum posted a preprint on August 19, 2026 asking whether a quantum kernel classifies those signals better than a conventional support vector machine. The methylation cohort covered 813 individuals with 188 cancers across 56 methylation targets; the fragmentomics cohort covered 718 individuals with 172 cancers across 473 genomic regions. Features were encoded with angle and dense-angle feature maps across circuits of 10 to 20 qubits, using three entanglement patterns, and the resulting fidelity kernels fed a precomputed-kernel support vector machine and a kernel-PCA logistic regression.
A split verdict, measured in simulation
On fragmentomics the quantum-kernel models reached held-out AUC values around 81 to 82 percent against a classical baseline near 78 to 79 percent. On methylation the ordering reversed, with the classical model centered around 83 to 84 percent and the quantum models between 80 and 82.5 percent. Widening from 20 to 40 features did not reliably help. Every kernel was computed by exact statevector simulation on ordinary computers, so no quantum processor was involved, and the authors list hardware execution under finite sampling and device noise as future work. Quentir places the work at TRL 3 of 9 on the quantum computing pillar and reads the split, rather than either half of it, as the finding.